ArticleEmerging infectious diseases2026
Neoehrlichiosis Causing Hemolytic Anemia in Patients Treated with Rituximab, Norway, 2024-2025.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoehrlichiosis is caused by infection with the tickborne intracellular bacterium Neoehrlichia mikurensis. We describe 3 cases of direct antiglobulin test-negative hemolytic anemia in rituximab-treated patients infected with tickborne N. mikurensis bacteria in Norway during 2024-2025. All 3 patients had splenomegaly and night sweats. The hemolysis ranged from mild with compensated hemolysis to severe transfusion-dependent hemolysis that resulted in splenectomy in 1 case. All patients experienced complete resolution of hemolytic anemia and other symptoms of infection after eradication therapy with doxycycline for 21 days. Neoehrlichiosis should be considered as a curable cause of hemolytic anemia in N. mikurensis-endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.